fda semaglutide compounding warning november 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines The Risks of Compounded Semaglutide

The platform offers nine distinct compounded semaglutide formulations from seven different pharmacy partners, plus brand-name options and a sublingual formulation

We have some literature so far that seems to suggest, again, resistance training is really helpful to mitigate some of that," said Cohen

Resistance training , because sustaining a lower weight with preserved lean mass is the real long-term win

This optimized weight GLP-1 bundle helps minimize digestive side effects while helping you reach your goals!*

A bipartisan coalition of 38 state Attorneys General have called on the FDA to take swift action against compounding pharmacies that "cut corners in pursuit of a quick profit" and sell knockoff drugs that could lead to "serious public health issues." The Ohio Attorney General recently issued a press release about letters it sent to 14 entities warning them to stop deceiving patients into believing that compounded drugs are approved by the FDA or have been reviewed for safety, effectiveness, or quality and declaring that patients "deserve clear and accurate information about the medication they're putting in their bodies." Similarly, in December 2024, the Illinois Attorney General issued cease-and-desist letters to five Chicagoland med spas advertising name brand medications like Wegovy and Ozempic but "instead offering unapproved versions of these products that may put people's health at risk." In addition, over a dozen Attorneys General have issued statements discussing the dangers posed by knockoff "semaglutide," including North Carolina, South Carolina, and Tennessee

The test identifies genetic variants in your GLP1R (rs6923761), GIPR, FTO, and MC4R pathways that influence your response to GLP-1 and GIP-based therapies